Technical Analysis for AYTUW - Aytu Bioscience Inc. Wt

Grade Last Price % Change Price Change
grade C 0.17 304.76% 0.1280
AYTUW closed up 304.76 percent on Friday, August 2, 2019, on 8 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A Up Up
See historical AYTUW trend table...

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 0.00%
Crossed Above 50 DMA Bullish 0.00%
MACD Bullish Centerline Cross Bullish 0.00%
MACD Bullish Signal Line Cross Bullish 0.00%
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Gapped Up Strength 0.00%
Fell Below 20 DMA Bearish 304.76%
Fell Below 50 DMA Bearish 304.76%
MACD Bearish Centerline Cross Bearish 304.76%

Older signals for AYTUW ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Aytu is a commercial-stage specialty pharmaceutical company focused on global commercialization of novel products in the field of urology. We are currently focused on addressing significant medical needs in the areas of hypogonadism, urological cancers, urinary tract infections and male infertility. We currently market Natesto (testosterone) nasal gel, a novel formulation of testosterone delivered via a discreet, easy-to-use nasal gel. Natesto is approved by the U.S. Food and Drug Administration, or FDA, for the treatment of hypogonadism (low testosterone) in men and is the only testosterone replacement therapy, or TRT, delivered via a nasal gel. Natesto offers multiple advantages over currently available TRTs and competes in a $2.4 billion market. We also currently market ProstaScint (capromab pendetide), the only radioimaging agent indicated to detect the prostate specific membrane antigen, or PSMA, in the assessment and staging of prostate cancer. We also market Primsol (trimethoprim hydrochloride) — the only FDA-approved trimethoprim-only oral solution for urinary tract infections. We have a focused pipeline, including MiOXSYSTM, a novel in vitro diagnostic device that is currently CE marked (which generally enables it to be sold within the European Economic Area and for which we intend to initiate a final clinical study to enable FDA clearance in the U.S.
Medicine RTT Pharmaceutical Organ Systems Alcohols Prostate Cancer Hormones Ketones Urinary Tract Infections Testosterone Androstanes Urinary Tract Infection U.S. Food And Drug Administration Hypogonadism In Vitro Diagnostic Device Testosterone Replacement Therapy Androgen Replacement Therapy Indium (111in) Capromab Pendetide Male Infertility Trimethoprim Only Oral Solution Urological Cancers
Is AYTUW a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 0 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Indicator Value
52 Week High 1.2
52 Week Low 0.02
Average Volume 13,263
200-Day Moving Average 0.0
50-Day Moving Average 0.0969
20-Day Moving Average 0.1027
10-Day Moving Average 0.0882
Average True Range 0.0458
ADX 18.78
+DI 56.857
-DI 33.5867
Chandelier Exit (Long, 3 ATRs ) 0.0366
Chandelier Exit (Short, 3 ATRs ) 0.1574
Upper Bollinger Band 0.2039
Lower Bollinger Band 0.0015
Percent B (%b) 0.83
BandWidth 197.078871
MACD Line 0.0036
MACD Signal Line 0.0004
MACD Histogram 0.0032
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.1700
Resistance 3 (R3) 0.1700 0.1700 0.1700
Resistance 2 (R2) 0.1700 0.1700 0.1700 0.1700
Resistance 1 (R1) 0.1700 0.1700 0.1700 0.1700 0.1700
Pivot Point 0.1700 0.1700 0.1700 0.1700 0.1700
Support 1 (S1) 0.1700 0.1700 0.1700 0.1700 0.1700
Support 2 (S2) 0.1700 0.1700 0.1700 0.1700
Support 3 (S3) 0.1700 0.1700 0.1700
Support 4 (S4) 0.1700